Glycotope's Fully Human and Glyco-Optimized Recombinant FSH-GEX Showed Superior Activity and Excellent Tolerability in a Phase II Clinical Trial for IVF
Glycotope GmbH, a global leader in developing therapeutic antibodies targeting glycosylated epitopes on cancer cells and optimising the sugar chains (glycosylation) of biopharmaceuticals, has announced results from the Phase II clinical trial with FSH-GEX for Assisted Reproductive Technologies.
Results showed that FSH-GEX has superior activity and excellent tolerability when compared with the standard treatment Gonal-f. FSH-GEX is the first fully human glycosylated FSH (follicle-stimulating hormone), recombinantly expressed in human cells and glyco-optimized to mimic endogenous human FSH.
The Phase II, multicenter, multinational, randomised clinical trial investigated the efficacy and safety of varying doses and schedules of FSH-GEX in comparison with daily 150 IU Gonal-f in 247 women undergoing artificial insemination by intracytoplasmic sperm injection (ICSI) treatment in an agonist protocol. FSH-GEX was tested in five dose cohorts, 52.5 IU, 75 IU, 112.5 IU and 150 IU daily doses, and 150 IU given every second day, compared with the standard daily dose of 150 IU Gonal-f.
The data show that FSH-GEX, even at half the biologic dose (75 IU FSH-GEX), is at least as active as Gonal-f (150 IU) in all FSH mediated parameters and endpoints. These data confirm the superior preclinical, Phase Ia and Ib data regarding biological activity and clinical efficacy.
For example, the FSH-GEX dose of 112.5 IU, showed superiority over all FSH mediated aspects and endpoints compared with a 33% higher Gonal-f standard dose including follicular response, as well as high biochemical (57.5%) and ongoing (50.0%) pregnancy rates. Particularly important for future clinical use are the statistically significantly improved numbers of retrieved oocyte complexes (+29.5%) and high quality metaphase II oocytes (+24.5%), as well as a strong trend for more pronuclear (PN) 2 oocytes (+21%) which could be observed in this dose regimen.
Furthermore, the results at a dose regimen with 150 IU FSH-GEX applied every second day and 75 IU FSH-GEX administered on a daily basis were fully comparable, allowing for a flexible or alternative dosing regimen with the same product.
The treatment with FSH-GEX was safe and very well tolerated, whereas Gonal-f showed the highest rate of OHSS (Ovarian hyperstimulation syndrome) during the trial. No inductions of anti drug antibody (ADA) responses were observed in FSH-GEX patients.
"FSH-GEX is the first of our glyco-optimized, fully human non-antibody molecules validating our unique GlycoExpress platform and proving our commitment to delivering better, clinically superior therapies combined with commercially attractive terms," said Dr Steffen Goletz, CEO, CSO and Founder of Glycotope.
"The superior activity and improved properties of FSH-GEX, which allows for lower FSH doses and the significantly improved numbers of high quality mature oocytes that can be achieved for IVF, are seen as a key driver for best clinical performances. These results strongly indicate not only a high relevance of FSH-GEX in the tested broad patient cohort, but also yield hope for women whose ovaries are particularly hard to stimulate and who are experiencing major difficulties in becoming pregnant. We are excited about these results and anticipate starting Phase III clinical trials in 2014," he added.
Related News
-
News CPHI Frankfurt 2022: Innovator Interview – DSM Biomedical
At CPHI Frankfurt we spoke to Anne-Cecile Bayne, Global Science & Innovation Lead Pharma and Medical Nutrition, and Marc Hendriks, Vice President Strategy & Business Development, on their expertise in nitrosamines and business strategy at DSM Biomedica... -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled. -
News Magic mushrooms could be used to treat mental health conditions
A compound found in magic mushrooms, psilocybin, could be used to treat mental health conditions and help patients suffering with severe depression, as shown by the results of the largest study of its kind to date. -
News UK-based partnership to launch DETERMINE study into rare cancer research
UK-based CRO Quanticate is set to partner with Cancer Research UK for the launch of the DETERMINE study focused on testing a range of existing and approved drugs and therapies on rare cancers. -
News FDA approves Thermo Fisher blood tests for wheat and sesame allergies
Both tests have been approved by the US regulator for in vitro diagnostic use -
News QIAGEN launches world’s first syndromic test for monkeypox
The test can distinguish between monkeypox and other diseases that cause similar symptoms. -
News Monkeypox Update: Vaccine shortage, sewage surveillance and global testing
As concern over the monkeypox outbreak continues to rise, we take a look at major developments from the first week of August. -
News CPHI Podcast Series: The importance of novel excipients for innovative drug development
The latest episode in the CPHI Podcast Series dives into the world of novel excipients and explores their importance for innovative drug development.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance